VipBlogSpots

The bispecific antibody therapeutics market is projected to grow at an annualized rate of ~16%, in t

The bispecific antibody therapeutics market is projected to grow at an annualized rate of ~16%, in the span of 2019 to 2030 Roots Analysis has done a detailed study on Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 370+ page report, which features 90+ figures and 110+ tables, please visit this link Key Market Insights          For more information, please visit https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html Table of Contents 3.1.                   Chapter Overview 3.2.                   Concept of an Antibody 3.3.                   Structure of an Antibody 3.4.                   Functions of an Antibody 3.5.                   Mechanism of Action of an Antibody 3.6.                   Concept of Monoclonal Antibodies 3.7.                   Antibody Therapeutics 3.8.                   Historical Evolution of Antibody Therapeutics                         3.9.                   Types of Advanced Antibody Therapeutics         3.9.1.                Fc Engineered and Glycoengineered Antibodies 3.9.2.                Antibody Fragments 3.9.3.                Fusion Proteins 3.9.4.                Intrabodies 3.9.5.                Bispecific Antibodies                         3.10.                 Bispecific Antibody Formats 3.10.1.              Single-Chain-based Formats (Fc Independent Antibody Formats) 3.10.1.1.           Tandem scFvs (single-chain variable fragments) and Triple bodies          3.10.1.2.           Bispecific Single-Domain Antibody Fusion Proteins         3.10.1.3.           Diabodies / Diabody Derivatives 3.10.1.4.           Fusion Proteins 3.10.1.5.           Fusion Proteins Devoid of Fc Regions    3.10.2.              Immunoglobulin G (IgG)-based Formats (Fc Dependent Antibody Formats)          3.10.2.1.           Quadromas       3.10.2.2.           Knobs-Into-Holes          3.10.2.3.           Dual Variable Domain Ig            3.10.2.4.           IgG-scFv           3.10.2.5.           Two-in-one or Dual Action Fab (DAF) Antibodies 3.10.2.6.           Half Molecule Exchange 3.10.2.7.           κλ- Bodies                                3.11.                 Mechanisms of Action of Bispecific Antibodies    3.11.1.             Retargeting Immune Effectors (NK Cells and T Cells) to Tumor Cells       3.11.2.              Directly Targeting Malignant / Tumor Cells 3.11.3.              Retargeting of Toxins 3.11.5.              Targeting Tumor Angiogenesis 3.11.6.              Other Mechanisms                         3.12.                 Applications of Bispecific Antibodies                         4                      MARKET OVERVIEW 4.1.                   Chapter Overview 4.2.
                  Bispecific Antibody Therapeutics: Developer Landscape 4.2.1.                Analysis by Year of Establishment 4.2.2.                Analysis by Company Size 4.2.3.
               Analysis by Geographical Location                         4.3.                   Bispecific Antibody Therapeutics: Clinical Pipeline 4.3.1.
               Analysis by Phase of Development 4.3.2.                Analysis by Target Antigen 4.3.3.                Analysis by Type of Antibody Format 4.3.4.
               Analysis by Mechanism of Action 4.3.5.                Analysis by Disease Indication 4.3.6.                Analysis by Therapeutic Area 4.3.7.                Analysis by Broader Disease Segment 4.3.8.
               Analysis by Route of Administration 4.3.9.                Analysis by Mode of Administration 4.3.10.              Analysis by Patient Segment 4.4.                   Bispecific Antibody Therapeutics: Early Stage Pipeline 4.4.1.
               Analysis by Phase of Development 4.4.2.                Analysis by Target Antigen 4.4.4.                Analysis by Mechanism of Action 4.4.5.
               Analysis by Therapeutic Area 4.4.6.                Analysis by Broader Disease Segment 4.6.                   Bispecific Antibody Therapeutics: Combination Therapy Candidates 4.7.                   Bispecific Antibody Therapeutics: Non-Industry Players 4.8.                   Emerging Novel Antibody Therapeutic Modalities                         5                      Bispecific Antibody Therapeutics: Technology Platforms 5.1.                   Chapter Overview 5.2.                   Bispecific Antibody Therapeutics: List of Technology Platforms 5.3.                   Bispecific Antibody Therapeutics: Technology Platform Profiles                         5.3.1.                Bispecific T-cell Engager (BiTE®) (Amgen) 5.3.1.1.
            Overview           5.3.1.2.             Technology Details        5.3.1.3.
            Structure of BiTE® Bispecific Antibodies 5.3.1.4.             Pipeline of BiTE® Bispecific Antibodies 5.3.1.5.
            Advantages of BiTE® Bispecific Antibodies        5.3.1.6.             Partnerships and Collaborations                         5.3.2.                DuoBody® (Genmab) 5.3.2.1.
            Overview           5.3.2.2.             Technology Details        5.3.2.3.
            Structure of DuoBody® Bispecific Antibodies      5.3.2.4.             Pipeline of DuoBody® Bispecific Antibodies       5.3.2.5.
            Advantages of DuoBody® Bispecific Antibodies 5.3.2.6.             Partnerships and Collaborations                         5.3.3.                Xmab™ Antibody Engineering Platform (Xencor) 5.3.3.1.
            Overview           5.3.3.2.             Technology Details        5.3.3.3.
            Pipeline of Xmab™ Bispecific Antibodies 5.3.3.4.             Advantages of Xmab™ Bispecific Antibodies      5.3.3.5.
            Partnerships and Collaborations                         5.3.4.                WuXibodyTM Bispecific Engineering Platform (WuXi Biologics) 5.3.4.1.             Overview           5.3.4.2.
            Pipeline of WuXibodyTM Bispecific Antibodies   5.3.4.3.             Advantages of WuXibodyTM Bispecific Antibodies          5.3.4.4.
            Partnerships and Collaborations                         5.3.5.                Anticalin® (Pieris Pharmaceuticals) 5.3.5.1.             Overview           5.3.5.2.
            Structure of Anticalin® Bispecific Fusion Proteins           5.3.5.3.             Pipeline of Anticalin® Bispecific Fusion Proteins 5.3.5.4.
            Advantages of Anticalin® Bispecific antibody Platform    5.3.5.5.             Partnerships and Collaborations                         5.3.6.                Azymetric™ (Zymeworks) 5.3.6.1.
            Overview           5.3.6.2.             Technology Details        5.3.6.3.
            Structure of Azymetric™ Bispecific Antibodies    5.3.6.4.             Pipeline of Azymetric™ Bispecific Antibodies      5.3.6.5.
            Advantages of the AzymetricTM Bispecific Antibodies     5.3.6.6.             Partnerships and Collaborations                         5.4.                   Geographical Distribution of Technology Providers         5.5.                   Bispecific Antibody Technology Platforms: Comparative Analysis                         6                      DRUG PROFILES 6.1.                   Chapter Overview 6.2.                   Marketed Drug Profiles                         6.2.1.                Blincyto™ / Blinatumomab / AMG103 / MT103 (Amgen) 6.2.1.1.
            Company Overview       6.2.1.1.1.          Financial Performance   6.2.1.2.             Drug Overview 6.2.1.2.1.          Mechanism of Action and Targets           6.2.1.2.2.          Dosage 6.2.1.2.3.          Current Development Status      6.2.1.2.4.          Development Process   6.2.1.2.5.          Annual Sales                             6.2.2.                Hemlibra® / Emicizumab / RG6013 / ACE910 / RO5534262 (Chugai Pharmaceutical / Roche)       6.2.2.1.
            Company Overview       6.2.2.1.1.          Financial Performance   6.2.2.2.             Drug Overview 6.2.2.2.1.          Mechanism of Action and Targets           6.2.2.2.2.          Dosage 6.2.2.2.4.          Development Process   6.2.2.2.5.          Annual Sales                             6.3.                   Late Stage Drug Profiles 6.4.                   RG7716 / RO6867461 / Faricimab (Roche / Genentech) 6.4.1                 Drug Overview 6.5.                   Ozoralizumab / TS-152 / ATN103 (Ablynx / Eddingpharm / Taisho Pharmaceuticals)         6.5.1                 Drug Overview 6.6.
                  ABT-165 (AbbVie)         6.6.1                 Overview of Drug, Current Development Status and Clinical Results        6.7.                   ABY-035 (Affibody)       6.7.1.                Drug Overview 6.8.                   AFM13 (Affimed)          6.8.1                 Drug Overview 6.9.
                  AMG 570 / MEDI0700 (Amgen) 6.9.1.                Drug Overview 6.10.                 KN026 (Alphamab)        6.10.1.             Drug Overview 6.11.                 KN046 (Alphamab) 6.11.1.             Drug Overview 6.12.                 M1095 / ALX-0761 (Merck / Ablynx / Avillion)      6.12.1.             Drug Overview 6.13.                 M7824 / Bintrafusp Alfa (Merck / GlaxoSmithKline)          6.13.1.             Drug Overview 6.14.                 MCLA-128 (Merus)        6.14.1.             Drug Overview 6.15.                 MEDI3902 / Gremubamab (MedImmune /AstraZeneca)   6.15.1.             Drug Overview 6.16.                 Drug Overview 6.17.                 REGN1979 (Regeneron)            6.17.1.             Drug Overview 6.18.     ZW25 (Zymeworks)       6.18.1.              Drug Overview                         7                      KEY INSIGHTS 7.1.                   Chapter Overview 7.2.                   Bispecific Antibody Therapeutics: Analysis by Therapeutic Area and Phase of Development         7.3.
                  Bispecific Antibody Therapeutics: Spider-Web Analysis based on Mechanism of Action    7.4.                   Bispecific Antibody Therapeutics: Two-Dimensional Scatter Plot Analysis based on Target Combinations    7.4.1                 Key Parameters 7.5.                   Logo Landscape: Analysis of Developers by Company Size                                 8                      BENCHMARK ANALYSIS: BIG PHARMA PLAYERS 8.1.                   Chapter Overview 8.2.
                  Top Pharmaceutical Companies 8.2.1.                Analysis by Target Antigen 8.2.2.                Analysis by Type of Antibody Format 8.2.3.                Analysis by Mechanism of Action 8.2.4.                Analysis by Therapeutic Area 8.2.5.                Analysis by Type of Partnership                         9                      PARTNERSHIPS AND COLLABORATIONS 9.1.                   Chapter Overview 9.2.                   Partnership Models 9.3.                   Bispecific Antibody Therapeutics: Partnerships and Collaborations 9.3.1.                Analysis by Year of Partnership 9.3.2.                Analysis by Type of Partnership 9.3.3.                Analysis by Therapeutic Area 9.3.4.                Most Active Developers: Analysis by Number of Partnerships 9.3.5.                Most Active Contract Manufacturers: Analysis by Number of Manufacturing Agreements   9.3.6.                Regional Analysis 9.3.7.                Intercontinental and Intracontinental Agreements                         10                     CONTRACT SERVICES FOR BISPECIFIC ANTIBODY THERAPEUTICS            10.1.                 Chapter Overview 10.2.                 Manufacturing of Bispecific Antibody Therapeutics 10.2.1.             Key Manufacturing Considerations and Challenges          10.2.2.              Contract Manufacturing Organizations (CMOs) 10.2.2.1.           Introduction to CMOs     10.2.2.2.           Bispecific Antibody Therapeutics: List of CMOs                         10.2.3.              Contract Research Organizations (CROs) 10.2.3.1.           Introduction to CROs     10.2.3.2.           Bispecific Antibody Therapeutics: List of CROs                           10.3.                 Key Considerations for Selecting a Suitable CMO / CRO Partner                         11                     CLINICAL TRIAL ANALYSIS 11.1.                 Chapter Overview 11.2.                 Methodology 11.3.                 Bispecific Antibody Therapeutics: Clinical Trial Analysis   11.3.1.              Analysis by Trial Registration Year 11.3.2.              Analysis by Trial Recruitment Status 11.3.3.              Analysis by Trial Phase 11.3.4.              Analysis by Trial Design 11.3.5.              Analysis by Disease Indication 11.3.6.              Analysis by Therapeutic Area 11.3.7.              Most Active Players 11.3.8.              Analysis by Number of Clinical Trials and Geography 11.3.9.              Analysis by Enrolled Patient Population and Geography                         12                     CASE STUDY: REGULATORY GUIDELINES FOR BISPECIFIC ANTIBODIES   12.1.                 Chapter Overview 12.2.                 Guidelines Issued by Regulatory Authorities 12.2.1.              US Food and Drug Administration (FDA) 12.2.1.1.           Pharma Companies Response to the FDA Draft Guidance                                   12.2.2.              World Health Organization (WHO) 12.2.3.              The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use                              13                     CASE STUDY: PROMOTIONAL / MARKETING STRATEGIES 13.1.                 Chapter Overview 13.2.                 Overview of Channels Used for Promotional Campaigns 13.3.                 Summary: Product Website Analysis 13.4.                 Summary: Patient Support Services and Informative Downloads                         13.5.                 Promotional Analysis: Blincyto™ 13.5.1.              Drug Overview 13.5.2.              Product Website analysis 13.5.2.1.           Messages for Healthcare Professionals 13.5.2.1.1.         For MRD Positive Bcell precursor ALL   13.5.2.1.2.         For Relapsed or Refractory B-cell precursor ALL 13.5.2.2.           Message for Patients     13.5.3.              Patient Support Services and Informative Downloads 13.5.4.              Other Promotional Strategies 13.5.4.1.           Presence in Conferences                                   13.6.                 Promotional Analysis: Hemlibra® 13.6.1.              Drug Overview 13.6.2.              Product Website Analysis 13.6.2.1.           Messages for Healthcare Professionals 13.6.2.1.1.         For Hemophilia A without Factor VIII Inhibitors    13.6.2.1.2.         For Hemophilia A with Factor VIII Inhibitors         13.6.2.3.           Messages for Patients   13.6.3.              Patient Support Services and Informative Downloads 13.6.3.1.           Co-pay Program            13.6.3.2.           Independent Co-pay Assistance Foundation       13.6.3.3.           Genentech Patient Foundation   13.6.4.              Other Promotional Strategies 13.6.4.1.           Presence in Conferences                                   14                     SWOT ANALYSIS 14.1.                 Chapter Overview 14.2.                 Strengths 14.3.                 Weaknesses 14.4.                 Opportunities 14.5.                 Threats 14.6.
                Concluding Remarks                         15                     MARKET FORECAST AND OPPORTUNITY ANALYSIS 15.1.                 Chapter Overview 15.2.                 Scope and Limitations 15.3.                 Forecast Methodology and Key Assumptions                         15.4.                 Overall Bispecific Antibody Therapeutics Market, 2019-2030 15.4.1.              Bispecific Antibody Therapeutics Market: Analysis by Therapeutic Area 15.4.2.              Bispecific Antibody Therapeutics Market: Analysis by Mechanism of Action 15.4.3.              Bispecific Antibody Therapeutics Market: Analysis by Target Antigen 15.4.4.              Bispecific Antibody Therapeutics Market: Analysis by Antibody Format 15.4.5.              Bispecific Antibody Therapeutics Market: Analysis by Key Players 15.4.6.              Bispecific Antibody Therapeutics Market: Analysis by Geography 15.5.                 Bispecific Antibody Market: Value Creation Analysis 15.6.                 Bispecific Antibody Therapeutics Market: Product-wise Sales Forecasts                         15.6.1.              Blincyto 15.6.1.1.           Target Patient Population          15.6.1.2.           Sales Forecast 15.6.1.3.           Net Present Value         15.6.1.4.           Value Creation Analysis                         15.6.2.              Hemlibra 15.6.2.1.           Target Patient Population          15.6.2.2.           Sales Forecast 15.6.2.3.           Net Present Value         15.6.2.4.           Value Creation Analysis                         15.6.3.              RG7716 15.6.3.1.           Target patient Population           15.6.3.2.           Sales Forecast 15.6.3.3.           Net Present Value         15.6.3.4.           Value Creation Analysis                         15.6.4.              Ozoralizumab 15.6.4.1.           Target Patient Population          15.6.4.2.           Sales Forecast 15.6.4.3.           Net Present Value         15.6.4.4.           Value Creation Analysis                         15.6.5.              ABY-035 15.6.5.1.           Target Patient Population          15.6.5.2.           Sales Forecast 15.6.5.3.           Net Present Value         15.6.5.4.           Value Creation Analysis                         15.6.6.              AFM13 15.6.6.1.           Target Patient Population          15.6.6.2.           Sales Forecast 15.6.6.3.           Net Present Value         15.6.6.4.           Value Creation Analysis                         15.6.7.              M1095 15.6.7.1.           Target Patient Population          15.6.7.2.           Sales Forecast 15.6.7.3.           Net Present Value         15.6.7.4.           Value Creation Analysis                         15.6.8.              MEDI3902 15.6.8.1.           Target Patient Population          15.6.8.2.           Sales Forecast 15.6.8.3.           Net Present Value         15.6.8.4.           Value Creation Analysis                         15.6.9.              ABT-981 15.6.9.1.           Target Patient Population          15.6.9.2.           Sales Forecast 15.6.9.3.           Net Present Value         15.6.9.4.           Value Creation Analysis                         15.6.10.            SAR156597       15.6.10.1.          Target Patient Population          15.6.10.2.          Sales Forecast 15.6.10.3.          Net Present Value         15.6.10.4.          Value Creation Analysis                         16                     CONCLUDING REMARKS                         17                     EXECUTIVE INSIGHTS 17.1.                 Chapter Overview          17.2.
                CytomX Therapeutics     17.2.1.             Company Snapshot       17.2.2.
             Interview Transcript: Siobhan Pomeroy, Senior Director, Business Development (Q3 2017)                                   17.3.                 F-star    17.3.1.
            Company Snapshot       17.3.2.             Interview Transcript: Jane Dancer, Chief Business Officer (Q3 2017)                                17.4.
                Innovent Biologics        17.4.1.             Company Snapshot       17.4.2.
            Interview Transcript: Yinjue Wang, Associate Director, Process Development (Q3 2017)                            17.5.                 Synimmune       17.4.1.
            Company Snapshot       17.4.2.              Interview Transcript: Ludger Große-Hovest, Chief Scientific Officer, and Martin Steiner, Chief Executive Officer Contact Details Gaurav Chaudhary +1 (415) 800 3415 [email protected] Source: Free Articles from ArticlesFactory.com .